American Century Companies Inc. decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 8.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 710,079 shares of the medical research company’s stock after selling 69,173 shares during the quarter. American Century Companies Inc. owned about 0.63% of Natera worth $39,224,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the stock. Fred Alger Management LLC increased its position in shares of Natera by 2.2% during the 4th quarter. Fred Alger Management LLC now owns 8,972,823 shares of the medical research company’s stock worth $360,438,000 after purchasing an additional 191,477 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Natera by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 8,312,584 shares of the medical research company’s stock worth $364,258,000 after acquiring an additional 371,740 shares during the period. State Street Corp boosted its stake in shares of Natera by 20.4% during the 2nd quarter. State Street Corp now owns 3,409,372 shares of the medical research company’s stock worth $120,828,000 after acquiring an additional 577,106 shares during the period. Norges Bank bought a new position in shares of Natera during the 4th quarter worth approximately $111,690,000. Finally, Eversept Partners LP boosted its stake in shares of Natera by 88.4% during the 4th quarter. Eversept Partners LP now owns 2,685,959 shares of the medical research company’s stock worth $107,895,000 after acquiring an additional 1,260,357 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.
Insider Transactions at Natera
In other news, CEO Steven Leonard Chapman sold 2,605 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $50.88, for a total transaction of $132,542.40. Following the completion of the transaction, the chief executive officer now directly owns 214,983 shares in the company, valued at $10,938,335.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Steven Leonard Chapman sold 2,605 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $50.88, for a total value of $132,542.40. Following the sale, the chief executive officer now directly owns 214,983 shares in the company, valued at $10,938,335.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Rabinowitz sold 800 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $47.83, for a total value of $38,264.00. Following the completion of the sale, the insider now owns 178,478 shares in the company, valued at $8,536,602.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,493 shares of company stock worth $1,401,628. Insiders own 9.42% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on NTRA
Natera Stock Performance
NTRA opened at $55.51 on Tuesday. The firm has a market cap of $6.36 billion, a P/E ratio of -11.52 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.69 and a current ratio of 3.85. The business’s fifty day moving average is $50.37 and its 200-day moving average is $51.22. Natera, Inc. has a 52-week low of $34.00 and a 52-week high of $59.75.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.12. The company had revenue of $261.40 million for the quarter, compared to analysts’ expectations of $241.67 million. Natera had a negative return on equity of 88.47% and a negative net margin of 54.97%. The business’s quarterly revenue was up 31.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.50) earnings per share. Sell-side analysts expect that Natera, Inc. will post -4.03 EPS for the current fiscal year.
Natera Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
- Five stocks we like better than Natera
- How to Evaluate a Stock Before Buying
- 3 Reasons High-Yield Bloomin’ Brands is About to Blossom
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 5 Computer Vision Stocks with a Clear Path to Growth
- How to Invest in the FAANG Stocks
- 3 Reasons Workday Stock Is Setting Up For A New Rally
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
